# WIA-BIO-020: Regenerative Medicine Specification v1.0

> **Standard ID:** WIA-BIO-020
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Regenerative Medicine Research Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Stem Cell Types and Classification](#2-stem-cell-types-and-classification)
3. [Regeneration Mechanisms](#3-regeneration-mechanisms)
4. [Tissue Engineering and Scaffolds](#4-tissue-engineering-and-scaffolds)
5. [Growth Factor Delivery Systems](#5-growth-factor-delivery-systems)
6. [Clinical Applications](#6-clinical-applications)
7. [Regulatory Requirements](#7-regulatory-requirements)
8. [Implementation Guidelines](#8-implementation-guidelines)
9. [Safety Protocols](#9-safety-protocols)
10. [References](#10-references)

---

## 1. Introduction

### 1.1 Purpose

This specification defines the comprehensive framework for regenerative medicine, encompassing stem cell therapies, tissue engineering, growth factor delivery, and clinical applications for tissue and organ regeneration.

### 1.2 Scope

The standard covers:
- Stem cell types, culture, and differentiation
- Tissue regeneration mechanisms and pathways
- Scaffold design and biomaterial integration
- Growth factor delivery systems
- Clinical applications and therapeutic protocols
- Regulatory compliance (FDA RMAT, EMA ATMP)

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - This standard aims to provide scientifically rigorous protocols for regenerative medicine that restore health, extend life, and improve quality of living for all humanity.

### 1.4 Terminology

- **Regeneration**: The biological process of renewing, restoring, and growing tissues/organs
- **Stem Cells**: Undifferentiated cells capable of self-renewal and differentiation
- **Scaffold**: Three-dimensional structure supporting tissue growth
- **Growth Factors**: Signaling proteins that stimulate cellular growth and differentiation
- **ECM**: Extracellular Matrix - structural and biochemical support network
- **Biocompatibility**: Ability of a material to perform without adverse biological response

---

## 2. Stem Cell Types and Classification

### 2.1 Embryonic Stem Cells (ESCs)

**Source**: Inner cell mass of blastocyst (day 5-6 embryo)

**Characteristics**:
- Pluripotent: Can differentiate into all cell types
- High proliferation rate
- Express OCT4, SOX2, NANOG markers
- Telomerase positive (unlimited division)

**Applications**:
- Disease modeling
- Drug screening
- Cellular therapy (pending ethical approval)

**Culture Conditions**:
```
Medium: mTeSR1 or E8
Substrate: Matrigel or vitronectin
Temperature: 37°C, 5% CO₂
Passage: Every 3-5 days (70-80% confluence)
Pluripotency markers: OCT4⁺, NANOG⁺, SSEA-4⁺
```

### 2.2 Induced Pluripotent Stem Cells (iPSCs)

**Source**: Reprogrammed somatic cells (fibroblasts, blood cells)

**Reprogramming Factors** (Yamanaka Factors):
- OCT4 (Octamer-binding transcription factor 4)
- SOX2 (Sex determining region Y-box 2)
- KLF4 (Kruppel-like factor 4)
- c-MYC (Cellular myelocytomatosis oncogene)

**Reprogramming Efficiency**:
```
η = (N_iPSC / N_initial) × 100%
```

Typical efficiency: 0.01% - 3% depending on method

**Advantages**:
- Patient-specific (autologous)
- No ethical concerns
- Unlimited cell source
- Disease modeling in patient cells

**Quality Control**:
- Karyotype analysis (normal 46 chromosomes)
- Pluripotency marker expression (>90%)
- Teratoma formation assay
- Differentiation potential to 3 germ layers
- Epigenetic reprogramming verification

### 2.3 Mesenchymal Stem Cells (MSCs)

**Sources**:
- Bone marrow (BM-MSCs)
- Adipose tissue (AD-MSCs)
- Umbilical cord (UC-MSCs)
- Dental pulp (DP-MSCs)

**Defining Criteria** (ISCT 2006):
1. Plastic adherence
2. Positive markers: CD73⁺, CD90⁺, CD105⁺ (>95%)
3. Negative markers: CD45⁻, CD34⁻, CD14⁻, CD19⁻, HLA-DR⁻ (<2%)
4. Tri-lineage differentiation: osteogenic, adipogenic, chondrogenic

**Differentiation Potential**:
```
Osteogenic: Bone (osteoblasts, osteocytes)
Adipogenic: Fat (adipocytes)
Chondrogenic: Cartilage (chondrocytes)
Myogenic: Muscle (myocytes)
Neurogenic: Neural cells (limited)
```

**Immunomodulatory Properties**:
- Secrete IL-10, TGF-β, PGE2
- Suppress T-cell proliferation
- Modulate macrophage polarization (M1→M2)
- Low immunogenicity (low HLA class I, no HLA class II)

### 2.4 Hematopoietic Stem Cells (HSCs)

**Source**: Bone marrow, peripheral blood, umbilical cord blood

**Markers**:
- Positive: CD34⁺, CD133⁺, CD90⁺
- Negative: Lineage markers (Lin⁻)

**Differentiation**:
```
HSCs → Myeloid lineage → RBCs, platelets, granulocytes, monocytes
HSCs → Lymphoid lineage → T cells, B cells, NK cells
```

**Clinical Use**:
- Bone marrow transplantation
- Treatment of leukemia, lymphoma
- Sickle cell disease, thalassemia
- Immune deficiencies

---

## 3. Regeneration Mechanisms

### 3.1 Cellular Regeneration Pathways

#### 3.1.1 Proliferation

**Cell Cycle Regulation**:
```
G1 → S → G2 → M → G1
```

**Key Regulators**:
- Cyclins (D, E, A, B)
- CDKs (Cyclin-Dependent Kinases)
- CDK inhibitors (p21, p27, p16)

**Proliferation Rate**:
```
P = N₀ × e^(rt)
```

Where:
- `P` = Cell population at time t
- `N₀` = Initial cell number
- `r` = Growth rate
- `t` = Time

#### 3.1.2 Differentiation

**Lineage Commitment Factors**:
- Transcription factors (RUNX2 for bone, PPARG for adipose)
- Epigenetic modifications (DNA methylation, histone acetylation)
- Signaling pathways (Wnt, BMP, Notch, Hedgehog)

**Differentiation Efficiency**:
```
D_eff = (N_differentiated / N_total) × 100%
```

Target efficiency: >80% for clinical applications

#### 3.1.3 Migration and Homing

**Chemotactic Gradient**:
```
v = μ × ∇C
```

Where:
- `v` = Migration velocity
- `μ` = Chemotactic sensitivity
- `∇C` = Concentration gradient

**Homing Factors**:
- SDF-1/CXCR4 axis
- VEGF (Vascular Endothelial Growth Factor)
- Selectins and integrins

### 3.2 Tissue Regeneration Rate

**Mathematical Model**:
```
dT/dt = α × C × G - β × T
```

Where:
- `T` = Tissue volume
- `C` = Cell density
- `G` = Growth factor concentration
- `α` = Regeneration coefficient
- `β` = Degradation coefficient

**Integration Score**:
```
I = (V_integrated / V_total) × F_vascular × F_mechanical
```

Target integration score: I ≥ 0.8

### 3.3 Angiogenesis (Blood Vessel Formation)

**VEGF Signaling**:
```
VEGF + VEGFR2 → ERK1/2, Akt → Endothelial proliferation
```

**Vessel Density**:
```
D_vessel = N_vessels / Area (vessels/mm²)
```

Healthy tissue: 200-400 vessels/mm²

**Sprouting Model**:
```
Tip cells → VEGF gradient
Stalk cells → Lumen formation
Pericytes → Vessel stabilization
```

---

## 4. Tissue Engineering and Scaffolds

### 4.1 Scaffold Design Principles

**Essential Properties**:
1. **Biocompatibility**: No toxic or inflammatory response
2. **Biodegradability**: Controlled degradation matching tissue growth
3. **Porosity**: 70-90% for nutrient diffusion
4. **Mechanical Strength**: Match native tissue
5. **Surface Chemistry**: Support cell adhesion

### 4.2 Scaffold Materials

#### 4.2.1 Natural Polymers

| Material | Source | Degradation | Applications |
|----------|--------|-------------|--------------|
| Collagen | Animal tissue | Enzymatic (MMP) | Skin, bone, cartilage |
| Gelatin | Denatured collagen | Enzymatic | Drug delivery, wound healing |
| Chitosan | Crustacean shells | Lysozyme | Cartilage, wound dressing |
| Hyaluronic Acid | ECM | Hyaluronidase | Cartilage, dermal fillers |
| Fibrin | Blood clotting | Plasmin | Wound healing, cell delivery |
| Alginate | Seaweed | Non-enzymatic | Cell encapsulation |

#### 4.2.2 Synthetic Polymers

| Material | Type | Degradation Time | Applications |
|----------|------|------------------|--------------|
| PLA | Polyester | 12-24 months | Bone fixation, sutures |
| PLGA | Copolymer | 1-12 months | Drug delivery, scaffolds |
| PCL | Polyester | 24-36 months | Long-term implants |
| PEG | Hydrophilic | Stable/tunable | Hydrogels, drug release |
| PU | Polyurethane | Variable | Cardiovascular devices |

### 4.3 Scaffold Fabrication Methods

**3D Printing (Bioprinting)**:
```
Resolution: 50-200 μm
Print speed: 1-10 mm/s
Cell viability: >85% post-print
Layer thickness: 100-500 μm
```

**Electrospinning**:
```
Fiber diameter: 50 nm - 5 μm
Voltage: 10-30 kV
Flow rate: 0.1-5 ml/h
Porosity: 70-95%
```

**Freeze Drying**:
```
Freezing: -20°C to -80°C
Primary drying: -10°C, <100 mTorr
Secondary drying: 20°C, <50 mTorr
Pore size: 50-300 μm
```

### 4.4 Scaffold Characterization

**Porosity Measurement**:
```
P = (1 - ρ_scaffold / ρ_material) × 100%
```

**Pore Size Distribution**: 100-500 μm for bone, 50-150 μm for cartilage

**Mechanical Testing**:
```
Young's Modulus (E) = σ / ε
```

Target values:
- Bone: 10-20 GPa
- Cartilage: 0.5-2 MPa
- Skin: 0.1-1 MPa
- Blood vessels: 1-10 MPa

**Degradation Rate**:
```
M_remaining(t) = M₀ × e^(-kt)
```

Where:
- `M_remaining` = Remaining mass
- `M₀` = Initial mass
- `k` = Degradation rate constant
- `t` = Time

---

## 5. Growth Factor Delivery Systems

### 5.1 Key Growth Factors

| Growth Factor | Function | Target Cells | Optimal Dose |
|--------------|----------|--------------|--------------|
| VEGF | Angiogenesis | Endothelial cells | 10-50 ng/ml |
| FGF-2 | Cell proliferation | Multiple | 5-20 ng/ml |
| TGF-β | ECM production | Fibroblasts | 1-10 ng/ml |
| BMP-2 | Bone formation | Osteoblasts | 50-200 ng/ml |
| PDGF | Wound healing | Fibroblasts | 10-100 ng/ml |
| IGF-1 | Cell growth | Multiple | 50-200 ng/ml |
| EGF | Epithelial growth | Keratinocytes | 5-50 ng/ml |
| BDNF | Neurogenesis | Neurons | 10-100 ng/ml |
| NGF | Nerve growth | Neurons | 50-200 ng/ml |

### 5.2 Delivery Methods

#### 5.2.1 Bolus Injection

**Advantages**: Simple, immediate effect
**Disadvantages**: Short half-life, burst release

**Pharmacokinetics**:
```
C(t) = C₀ × e^(-kt)
```

Half-life: 2-24 hours for most growth factors

#### 5.2.2 Scaffold-Based Delivery

**Release Kinetics**:
```
M_released(t) = M_total × (1 - e^(-kt))
```

**Release Patterns**:
- Immediate release: 50-80% in 24h
- Sustained release: 10-20% per week
- Controlled release: Programmed pattern

#### 5.2.3 Encapsulation (Microspheres)

**Size Range**: 1-200 μm

**Release Mechanisms**:
1. Diffusion through polymer matrix
2. Polymer degradation
3. Osmotic pressure

**Encapsulation Efficiency**:
```
E_eff = (M_encapsulated / M_initial) × 100%
```

Target: >70%

#### 5.2.4 Gene Delivery (Plasmid/Viral)

**Viral Vectors**:
- Adenovirus: High efficiency, transient
- Lentivirus: Stable integration
- AAV: Safe, long-term expression

**Non-Viral**:
- Plasmid DNA
- mRNA
- Lipid nanoparticles

### 5.3 Combination Therapy

**Synergistic Effects**:
```
Effect_combined > Effect_A + Effect_B
```

**Examples**:
- VEGF + FGF-2: Enhanced angiogenesis (2-3× increase)
- BMP-2 + TGF-β3: Improved bone formation
- NGF + BDNF: Superior neural regeneration

---

## 6. Clinical Applications

### 6.1 Cardiac Regeneration

**Target**: Post-myocardial infarction (MI) heart repair

**Cell Sources**:
- iPSC-derived cardiomyocytes
- Cardiac progenitor cells
- MSCs (paracrine effects)

**Delivery Methods**:
- Direct injection into myocardium
- Intracoronary infusion
- Cardiac patch application

**Protocols**:
```
Cell dose: 2-5 × 10⁸ cells
Delivery timing: 2-4 weeks post-MI
Growth factors: VEGF, FGF-2, IGF-1
Scaffold: Fibrin or alginate hydrogel
```

**Success Metrics**:
- Ejection fraction improvement: >5%
- Infarct size reduction: >15%
- Vessel density increase: >30%

### 6.2 Neural Regeneration

**Target**: Spinal cord injury, stroke, neurodegenerative diseases

**Cell Sources**:
- Neural progenitor cells (NPCs)
- iPSC-derived neurons
- Schwann cells (peripheral nerves)

**Differentiation**:
```
iPSCs → Neural rosettes → NPCs → Neurons/Astrocytes/Oligodendrocytes
```

**Growth Factors**:
- BDNF (Brain-Derived Neurotrophic Factor)
- NGF (Nerve Growth Factor)
- NT-3 (Neurotrophin-3)
- GDNF (Glial-Derived Neurotrophic Factor)

**Protocols**:
```
Cell dose: 5-10 × 10⁶ cells
Injection: Intraspinal or intracerebral
Scaffold: Hyaluronic acid or chitosan
Immunosuppression: Cyclosporine or tacrolimus
```

**Success Metrics**:
- Axon regeneration: >500 μm
- Functional recovery: ASIA scale improvement
- Electrophysiology: Restored conduction

### 6.3 Bone Regeneration

**Target**: Non-union fractures, critical-size defects, osteoporosis

**Cell Sources**:
- BM-MSCs
- Adipose-derived MSCs
- Periosteal cells

**Osteogenic Differentiation**:
```
MSCs + BMP-2 + Dexamethasone + β-glycerophosphate + Ascorbic acid
    → Osteoblasts → Mineralized matrix
```

**Scaffold Requirements**:
- Material: Hydroxyapatite, β-TCP, PLGA
- Porosity: 70-80%
- Pore size: 200-400 μm
- Compressive strength: >5 MPa

**Protocols**:
```
Cell seeding: 5 × 10⁶ cells/cm³
BMP-2 dose: 100-200 μg
Culture time: 7-14 days in vitro
Implantation: Direct surgical placement
```

**Success Metrics**:
- Bone volume/Total volume (BV/TV): >40%
- Mechanical strength: >70% native bone
- Complete bridging: 3-6 months

### 6.4 Cartilage Repair

**Target**: Osteoarthritis, focal cartilage defects

**Cell Sources**:
- Autologous chondrocytes (ACI)
- MSCs
- iPSC-derived chondrocytes

**Chondrogenic Differentiation**:
```
MSCs + TGF-β3 + BMP-6 + Dexamethasone → Chondrocytes
    → Collagen II, Aggrecan, SOX9⁺
```

**Protocols**:
```
Cell dose: 1-5 × 10⁶ cells/cm²
Scaffold: Collagen type I/III or hyaluronic acid
Growth factors: TGF-β3 (10 ng/ml), BMP-6 (100 ng/ml)
Implantation: Arthroscopic or open surgery
```

**Success Metrics**:
- ICRS (International Cartilage Repair Society) score: ≥8/12
- Collagen II expression: >70%
- GAG content: >60% native cartilage

### 6.5 Skin Regeneration

**Target**: Burns, chronic wounds, diabetic ulcers

**Cell Sources**:
- Autologous keratinocytes
- Fibroblasts
- MSCs

**Bioengineered Skin**:
```
Dermal layer: Fibroblasts + collagen scaffold
Epidermal layer: Keratinocytes + fibrin glue
Full-thickness: Bilayer construct
```

**Protocols**:
```
Cell expansion: 2-3 weeks
Keratinocyte density: 5 × 10⁴ cells/cm²
Fibroblast density: 1 × 10⁴ cells/cm²
Growth factors: EGF, KGF, PDGF
```

**Success Metrics**:
- Wound closure: >90% at 3 weeks
- Scar formation: Minimal (Vancouver Scar Scale <5)
- Pigmentation: Restored within 6 months

---

## 7. Regulatory Requirements

### 7.1 FDA RMAT (Regenerative Medicine Advanced Therapy)

**Criteria for RMAT Designation**:
1. Regenerative medicine therapy (cell/gene therapy)
2. Intended to treat/modify/cure serious condition
3. Preliminary clinical evidence of potential benefit

**Expedited Programs**:
- Fast Track
- Breakthrough Therapy
- Priority Review
- Accelerated Approval

**Submission Requirements**:
- Pre-IND meeting documentation
- CMC (Chemistry, Manufacturing, Controls) section
- Nonclinical studies (toxicology, biodistribution)
- Clinical trial protocols (Phase I/II/III)

### 7.2 EMA ATMP (Advanced Therapy Medicinal Products)

**Categories**:
1. Gene therapy medicinal products
2. Somatic cell therapy medicinal products
3. Tissue engineered products
4. Combined ATMPs

**Requirements**:
- Quality (GMP manufacturing)
- Safety (preclinical studies)
- Efficacy (clinical trials)
- Risk management plan
- Pharmacovigilance system

### 7.3 GMP (Good Manufacturing Practice)

**Critical Parameters**:
- Clean room: ISO Class 5 (Class 100)
- Air quality: <3,520 particles ≥0.5 μm/m³
- Temperature: 20-24°C
- Humidity: 30-60% RH
- Sterility testing: <1 CFU/sample

**Documentation**:
- Master Cell Bank (MCB) characterization
- Batch production records
- Quality control testing results
- Chain of custody documentation

### 7.4 Quality Control Testing

**Release Criteria**:

| Test | Acceptance Criteria |
|------|---------------------|
| Sterility | No growth (14 days) |
| Endotoxin | <5 EU/kg body weight |
| Mycoplasma | Negative |
| Viability | >70% |
| Identity | Marker expression >90% |
| Purity | Contaminating cells <5% |
| Potency | Functional assay specific |
| Karyotype | Normal (if applicable) |

---

## 8. Implementation Guidelines

### 8.1 Required Components

Any WIA-BIO-020 compliant system must include:

1. **Cell Source Management**: Track origin, passage, characterization
2. **Differentiation Protocols**: Standardized, validated methods
3. **Quality Control**: Real-time monitoring and testing
4. **Growth Factor Calculator**: Optimize dosing and timing
5. **Scaffold Designer**: Material, porosity, mechanics optimization
6. **Clinical Tracker**: Patient outcomes and safety monitoring

### 8.2 API Interface

#### 8.2.1 Calculate Regeneration Rate
```typescript
interface RegenerationRequest {
  tissueType: 'cardiac' | 'neural' | 'bone' | 'cartilage' | 'skin';
  cellDensity: number;      // cells/ml
  timeFrame: number;        // days
  growthFactors: string[];
}

interface RegenerationResponse {
  rate: number;             // cells/day
  recoveryPercentage: number;
  timeToComplete: number;   // days
  feasibility: 'high' | 'medium' | 'low';
}
```

#### 8.2.2 Assess Cell Survival
```typescript
interface SurvivalRequest {
  cellType: string;
  viableCells: number;
  totalCells: number;
  cultureConditions: string;
}

interface SurvivalResponse {
  survivalRate: number;     // 0-100%
  viability: 'excellent' | 'good' | 'fair' | 'poor';
  recommendations: string[];
}
```

#### 8.2.3 Design Scaffold
```typescript
interface ScaffoldRequest {
  tissueType: string;
  material: string;
  porosity: number;         // 0-1
  size: number;             // cm³
  mechanicalRequirements: {
    youngModulus?: number;  // MPa or GPa
    compressiveStrength?: number;
  };
}

interface ScaffoldResponse {
  design: {
    material: string;
    dimensions: { width: number; height: number; depth: number };
    poreSize: number;       // μm
    porosity: number;
    degradationTime: number; // months
  };
  mechanical: {
    youngModulus: number;
    tensileStrength: number;
    compressiveStrength: number;
  };
  biocompatibility: 'excellent' | 'good' | 'acceptable';
}
```

### 8.3 Data Formats

#### 8.3.1 Cell Characterization
```json
{
  "cellType": "iPSC",
  "passage": 15,
  "markers": {
    "OCT4": 0.95,
    "NANOG": 0.92,
    "SSEA4": 0.94
  },
  "viability": 0.89,
  "karyotype": "46,XY",
  "mycoplasma": "negative",
  "doubling_time_hours": 24
}
```

#### 8.3.2 Tissue Regeneration
```json
{
  "tissue": "cardiac",
  "patient_id": "P12345",
  "baseline": {
    "ejection_fraction": 0.35,
    "infarct_size_cm2": 15
  },
  "post_treatment": {
    "ejection_fraction": 0.42,
    "infarct_size_cm2": 10,
    "vessel_density": 320
  },
  "improvement_percentage": 20
}
```

### 8.4 Error Handling

Standard error codes:

| Code | Meaning | Action |
|------|---------|--------|
| B001 | Cell contamination detected | Discard culture, decontaminate |
| B002 | Low viability (<70%) | Optimize culture conditions |
| B003 | Marker expression insufficient | Extend culture, retest |
| B004 | Scaffold degradation too fast | Change material or crosslinking |
| B005 | Growth factor instability | Add stabilizers, reduce temperature |
| B006 | Immune rejection risk | HLA matching, immunosuppression |

---

## 9. Safety Protocols

### 9.1 Pre-Clinical Testing Checklist

- [ ] In vitro biocompatibility (ISO 10993)
- [ ] Tumorigenicity assay (nude mice)
- [ ] Biodistribution study
- [ ] Toxicology (acute, subacute, chronic)
- [ ] Immunogenicity assessment
- [ ] Off-target differentiation check
- [ ] Long-term genomic stability

### 9.2 Clinical Safety Monitoring

**Adverse Events**:
- Immune rejection
- Infection
- Tumor formation
- Ectopic tissue formation
- Thrombosis

**Monitoring Schedule**:
```
Week 1: Daily
Week 2-4: Every 3 days
Month 2-6: Weekly
Month 7-12: Monthly
Year 2+: Quarterly
```

**Biomarkers**:
- Complete blood count (CBC)
- Liver function tests (ALT, AST)
- Kidney function (creatinine, BUN)
- Inflammation markers (CRP, IL-6)
- Tumor markers (AFP, CEA, if applicable)

### 9.3 Dose Escalation

**3+3 Design**:
```
Level 1: 1 × 10⁶ cells (3 patients)
Level 2: 5 × 10⁶ cells (3 patients)
Level 3: 1 × 10⁷ cells (3 patients)
Level 4: 5 × 10⁷ cells (3 patients)
```

**DLT Criteria** (Dose-Limiting Toxicity):
- Grade ≥3 adverse event
- Serious adverse event (SAE)
- Death within 30 days

### 9.4 Long-Term Follow-Up

**Duration**: Minimum 5 years for cell therapy, 15 years for gene therapy

**Assessments**:
- Functional outcomes (disease-specific)
- Quality of life (SF-36, EQ-5D)
- Imaging (MRI, CT, ultrasound)
- Biopsy (if indicated)
- Genetic stability (karyotype, CGH array)

---

## 10. References

### 10.1 Scientific Literature

1. Takahashi, K., Yamanaka, S. (2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors." Cell 126(4): 663-676.
4. Langer, R., Vacanti, J.P. (1993). "Tissue engineering." Science 260(5110): 920-926.
5. Khademhosseini, A., Langer, R. (2016). "A decade of progress in tissue engineering." Nature Protocols 11: 1775-1781.

### 10.2 Regulatory Guidelines

- FDA Guidance: "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use" (2020)
- EMA Guideline: "Guideline on human cell-based medicinal products" (2008)
- ICH Q5A(R1): "Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin" (1999)
- ISO 10993: "Biological evaluation of medical devices"

### 10.3 Clinical Trial Registries

- ClinicalTrials.gov (USA)
- EU Clinical Trials Register
- ISRCTN Registry (International)

### 10.4 WIA Standards

- WIA-BIO-002: Cell Culture Technology
- WIA-BIO-005: Tissue Engineering
- WIA-HEALTH: Patient Health Monitoring
- WIA-OMNI-API: Universal Biomedical API

---

## Appendix A: Growth Factor Table (Comprehensive)

| Factor | MW (kDa) | Half-life | Stability | Storage |
|--------|----------|-----------|-----------|---------|
| VEGF-A | 38-45 | 2-4 h | Moderate | -80°C |
| FGF-2 | 18 | 3-7 h | High | -20°C |
| TGF-β1 | 25 | 2-3 min | Low (pH sensitive) | -80°C |
| BMP-2 | 26 | 7 min | High | -20°C |
| PDGF-BB | 24 | 2-4 h | Moderate | -80°C |
| IGF-1 | 7.6 | 12-15 h | High | -20°C |
| EGF | 6 | 8-10 h | High | -20°C |
| BDNF | 27 | 1-10 min | Low | -80°C |
| NGF | 26 | 2-3 h | Moderate | -80°C |
| HGF | 82 | 5-10 min | Moderate | -80°C |

## Appendix B: Scaffold Material Comparison

| Property | Collagen | Chitosan | PLGA | PCL | Alginate |
|----------|----------|----------|------|-----|----------|
| Origin | Animal | Natural | Synthetic | Synthetic | Natural |
| Biocompatibility | Excellent | Good | Good | Good | Excellent |
| Cell adhesion | Excellent | Good | Poor (needs modification) | Poor | Poor |
| Degradation | 2-8 weeks | 4-12 weeks | 1-12 months | 24-36 months | Days-weeks |
| Mechanical strength | Low-Medium | Low | Medium-High | High | Low |
| Cost | High | Medium | Low | Low | Low |

---

**弘益人間 (홍익인간) · Benefit All Humanity**

*WIA-BIO-020 Specification v1.0*
*© 2025 SmileStory Inc. / WIA*
*MIT License*
